<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A9426E3-7F35-48FC-BD72-3776C8F90A4A"><gtr:id>4A9426E3-7F35-48FC-BD72-3776C8F90A4A</gtr:id><gtr:name>Grants Admin Office</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Clinical Neuroscience</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A9426E3-7F35-48FC-BD72-3776C8F90A4A"><gtr:id>4A9426E3-7F35-48FC-BD72-3776C8F90A4A</gtr:id><gtr:name>Grants Admin Office</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/55617AE1-8AD6-49F7-BABE-AD783C499034"><gtr:id>55617AE1-8AD6-49F7-BABE-AD783C499034</gtr:id><gtr:firstName>Ammar</gtr:firstName><gtr:surname>Al-Chalabi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3196ED83-0287-425C-9340-FA48D7744238"><gtr:id>3196ED83-0287-425C-9340-FA48D7744238</gtr:id><gtr:firstName>Irene</gtr:firstName><gtr:otherNames>Julie</gtr:otherNames><gtr:surname>Higginson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A8264B87-E81C-42BC-905F-627E39A746DB"><gtr:id>A8264B87-E81C-42BC-905F-627E39A746DB</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>McDermott</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E5515A4A-3DDA-4476-A398-AA5AAD207BD1"><gtr:id>E5515A4A-3DDA-4476-A398-AA5AAD207BD1</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Tappenden</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/97B1547D-A1E3-46EA-A9CC-D606A7FFCC1A"><gtr:id>97B1547D-A1E3-46EA-A9CC-D606A7FFCC1A</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:surname>Stahl</gtr:surname><gtr:orcidId>0000-0001-7987-6619</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=ES%2FL008238%2F1"><gtr:id>81D0A377-D998-40F3-B549-219B4E64C255</gtr:id><gtr:title>A Programme for ALS Care in Europe (ALS-CarE)</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>ES/L008238/1</gtr:grantReference><gtr:abstractText>Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that strikes in the prime of life. There are currently no effective disease modifying therapies for ALS and death usually occurs within 3 years of symptom onset. Management is palliative and is aimed at maximising quality of life and minimising the burden of disease. The complexity and rapidly progressive nature of ALS requires a responsive multidisciplinary care system that that is built on reliable disease staging and evidence based symptom management.

The purpose of ALS-CarE is to incorporate detailed clinical information drawn from population based sources into a responsive care programme. A standardised staging system will be validated, and quality of life and patient experiences will be measured and management optimised across disease stages from diagnosis to end of life. Health economic analysis will identify key differences in resource utilisation and will be useful for pharmaco-economic analyses of new therapeutics. The completed project will provide a user-friendly best practice framework for ALS that can be modified for management of other neurodegenerative diseases.</gtr:abstractText><gtr:potentialImpactText>For an Impact Summary relating to societal and economic impacts, please see the attached document &amp;quot;Pathways to Impact&amp;quot;. This is a summary of the Academic Impact.

Although our partners come from six countries with very different health care systems and different cultures, all are members of a highly successful European ALS Consortium (ENCALS), with extensive existing collaborations in basic, translational and clinical aspects of ALS. The strength of this application, underpinned by our collective experience as key European ALS clinician scientists and healthcare researchers, gives us a unique opportunity to study and learn, both from the common elements and the differences between our systems and our services. The benefits of this proposal are further enhanced by existing support provided by the Health Research Board in Ireland to ALS-CarE Partner 1 (Dublin). Thanks to the work already undertaken within this three-year project, much of the infrastructure and methodological approaches needed for ALS-CarE are currently under development and will be readily available to the ALS-CarE consortium at the start of the project, thus expediting the research programme. The outcome will provide an expert-led evidence-based and user-friendly protocol for management of ALS in Europe that can also operate as a guide and
educational tool for non-specialist services and voluntary groups providing care for ALS. Moreover, on completion, the entire programme will be available for adaptation to other neurodegenerative conditions such as Alzheimer's Disease, Parkinson's Disease and frontotemporal dementia.

In order to establish a metric by which care can be measured from a health economic perspective, a strong focus will be placed on the components of the care matrix that are considered most useful by the users (patients and families). This will be achieved by integrating the outcome of a qualitative project currently funded by the Irish Health Research Board to examine user attitudes towards ALS care with the care matrix. As part of this process, patients and carers, (including international stakeholder organizations such as PatientslikeMe http://www.patientslikeme.com/research) will be provided with an opportunity to comment extensively on the usefulness of the care programme, yielding qualitative data that will be analysed to identify core themes that can be incorporated into existing and novel health economic tools.

ALS-CarE will seek regular advice through the Executive Board from eminent Health Services Researchers and Health Economists assembled in the Scientific Advisory Board (SAB) and stakeholders in the Stakeholder Platform. The SAB will provide expert advice on the content, quality of the deliverables, ethical issues, general philosophy and direction of the project, corrective measures in the content of the work if necessary and the dissemination and exploitation of project results. The SAB will be chaired by Dr. Brian Dickie from MNDA. The Consortium has obtained full commitment from ALS patient organisations from all participating countries.

Knowledge exchange within the consortium will be facilitated by yearly consortium meetings and an exchange program. Once every year a consortium meeting will be organised. During this meeting all the partners will discuss the project progress and will exchange other relevant knowledge in their field. For the last consortium meeting representatives of all national funding agencies and policy bodies will be invited to share the final results of the project. The ALSCarE consortium acknowledges that training of young researchers and mobility within the consortium will be beneficial for maximal knowledge transfer. Therefore, all consortium partners will exchange three of their (PhD) students and/or postdoctoral researchers for 2 - 4 months during the duration of this project. The aim will be to exchange knowledge of the main research techniques between different consortium members.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/924BE15C-91F2-4AAD-941A-3F338324B6AE"><gtr:id>924BE15C-91F2-4AAD-941A-3F338324B6AE</gtr:id><gtr:name>ESRC</gtr:name></gtr:funder><gtr:start>2014-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>254763</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Trinity College Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>ALS-CarE</gtr:description><gtr:id>874ADC33-1108-40D8-86C6-51EB0E9EEEA8</gtr:id><gtr:impact>See form under publications. Multidisciplinary including health services research, environmental studies and phenotyping.</gtr:impact><gtr:outcomeId>545f8b5a09e924.47472178-1</gtr:outcomeId><gtr:partnerContribution>Epidemiology, cognitive and phenotyping expertise, as well as qualitative expertise</gtr:partnerContribution><gtr:piContribution>Epidemiology, cognitive and phenotyping data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>25th International Symposium on ALS/MND (Brussels)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E74BA93D-134E-496F-A3EB-3076E22CB7CF</gtr:id><gtr:impact>At the International Symposium on ALS/MND this year over 800 people came together to hear the latest research findings.
The 26th annual event was a truly international affair, with scientists and health professionals from over 30 countries attending. The clinical trials session was a great example of this and featured presentations from Japanese, American and South Korean researchers.
Everyone who attended the Symposium was encouraged by the biomedical and care research that was discussed, including interesting conversations on how we classify MND, and how MND originates and spreads from one part of the body to another. There was a particularly thought provoking session on the way neurologists communicate a diagnosis of MND, put very eloquently by Juliet Jacobsen as 'delivering the horrible information in a hopeful way'.</gtr:impact><gtr:outcomeId>56dd708bc9e697.91762376</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.mndassociation.org/research/international-symposium/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TRICALS training</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>06B46BA9-F3FE-4103-AC3A-16FBF79FA75C</gtr:id><gtr:impact>Training in clinical staging for ALS for members of the TRICALS consortium. An analysis of responses from the training has been submitted for publication.</gtr:impact><gtr:outcomeId>58a2ea1f7b6c85.91513587</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.tricals.org/#1487071717028</gtr:url><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote presentation at International Symposium of ALS/MND Associations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B84E6D2D-1169-4758-B2CE-DF825135DE3C</gtr:id><gtr:impact>Extensive discussion of the content

Invitations to speak at further conferences, two invitations to write reviews for Nature Reviews Neurology (both taken up), invitation to submit paper to Lancet Neurology and to visit the offices.</gtr:impact><gtr:outcomeId>5460fb0499a4a1.61114683</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Joint JPND Consortia Meeting, London Heathrow</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8498D2E9-149F-4853-887B-0CD0D95CB588</gtr:id><gtr:impact>Joint JPND Consortia Meeting, 06 - 07 October 2014, London Heathrow:
In October 2014 a 1.5-day Joint JPND Consortia Meeting was organized by Project Coordinator (UK1) in London Heathrow, UK. The new format of involving four different JPND-funded project consortia (STRENGTH, SOPHIA, ALS-CarE and NEEDS in ALS) and compiling a meeting programme out of thematic sessions across four projects was a great success and all project coordinators are willing to continue this in the future. Fifty stakeholders including project coordinators, project partners, external collaborators, as well as special guests attended the sessions over two days in London.</gtr:impact><gtr:outcomeId>56d9bddfe94a95.47198355</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>General research dissemination videos on YouTube</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>919F4AB2-32AF-4797-BC7F-EB4EF295484F</gtr:id><gtr:impact>Multiple videos on YouTube, responding to interviews on ALS research</gtr:impact><gtr:outcomeId>58a2ed187db8e3.61005635</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.youtube.com/results?search_query=ammar+al-chalabi+als</gtr:url><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Amsterdam City Swim 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7560AB33-59A5-46DF-BDCB-2BDF03F833DA</gtr:id><gtr:impact>Professor Ammar Al-Chalabi took part in the 2 km Amsterdam City Swim 2015 which took place on Sunday, 06 September in Amsterdam's Central Canal and successfully raised &amp;pound;540.00 for the Motor Neurone Disease Association.</gtr:impact><gtr:outcomeId>56ddb06a80e164.42926084</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.justgiving.com/AmmarAl-Chalabi</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mitsubishi Tanabe Pharma workshop on clinical staging measures in ALS</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>15DC16D3-FF6C-4ADF-9F60-FF02D610D7B4</gtr:id><gtr:impact>A formal workshop on different outcome measures for clinical trials in ALS, and specifically the benefits of clinical staging systems. Clinical staging (and specifically King's Clinical Staging for ALS) was regarded as a major benefit for clinical trials and the basis of a research output (two poster presentations and a platform presentation) from the pharmaceutical company at the December International ALS Symposium in Dublin.</gtr:impact><gtr:outcomeId>58a2e90699c195.41999364</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.als.net/news/global-als-research-progress-a-report-from-2016-international-symposium-in-dublin/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>26th International Symposium on ALS/MND (Orlando)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C6A7269C-2F58-4E9B-A97A-A7C585893119</gtr:id><gtr:impact>The symposium is the largest medical and scientific conference specific to MND and is the premier event in the MND research calendar for discussion on the latest advances in research and clinical management.

Each year, the symposium attracts over 800 delegates, representing the energy and dynamism of the global MND research community.</gtr:impact><gtr:outcomeId>56dda276ca48f8.70063236</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.encals.eu/past-meeting/encals-satellite-meeting-2015-orlando/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ask the Experts Panel at International Symposium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DA7800AA-B0DB-4822-A3C5-DC7618F59069</gtr:id><gtr:impact>A live audience and online audience watched a presentation and then asked questions on ALS research</gtr:impact><gtr:outcomeId>58a2ec3fab4506.37085934</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=U98WU4Zzu8s</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Staging presentation at Cytokinetics meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BA0A473E-12E9-4580-8B75-DFD2B3FD3DD1</gtr:id><gtr:impact>About 220 participants attended in person, with more attending online. This was a set of three presentations on outcome measures for ALS clinical trials, with major audience participation, including voting on different measures. The number of people stating they would incorporate clinical staging as a routine part of their everyday practice increased from 5% to 25% by the end of the discussion.</gtr:impact><gtr:outcomeId>58a2e78fb2f068.94947846</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://alsmndmeasures.com/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA information video on our research</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>199B3651-1506-4E5F-9AF4-AEC1FD8472C3</gtr:id><gtr:impact>A YouTube video posted also on the Motor Neurone Disease Association website, describing our research.</gtr:impact><gtr:outcomeId>58a2eb299868a4.07244144</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://youtu.be/tKz81aFVB04</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ENCALS meeting 2015 Dublin</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5B5AFEB3-80BB-493E-A749-F9D59A3BE089</gtr:id><gtr:impact>The ENCALS meeting is an important forum for the European MND community. The aim of the meeting is to encourage younger researchers to present their data, and to meet and interact with more established members of the community.

The program highlighted state-of the-art science and clinical practice in the field of ALS. The focus was on Genes and Genomics, Cognition, C9orf72 and Novel Therapeutics, Imaging, TDP: RNA Metabolism and Disease Pathogenesis, Disease Models and Pathogenesis and Novel Biomarkers. Top international speakers provided cutting edge overviews. 

The meeting in Dublin was a great success with over 30 oral presentations and 80 poster presentations and many opportunities for young researchers to enhance their network.</gtr:impact><gtr:outcomeId>56dd971f209d54.74189584</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:url>http://www.encals.eu/news/encals-meeting-2015-dublin/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ENCALS meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FEC322BF-C31D-4165-884C-4D1ACA380EA2</gtr:id><gtr:impact>About 50 people attended the European Network for the Cure of ALS satellite meeting at the International ALS Symposium in Dublin. There was significant discussion around clinical staging, multistep models, and genetics of ALS</gtr:impact><gtr:outcomeId>58a2e514e6c4b7.63211664</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.encals.eu/wp-content/uploads/2016/09/20161206-program-ENCALS-satellite-Dublin.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ENCALS meeting 2014 Leuven</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5D7D200E-1F0D-4005-8DAC-2FDFBADD964C</gtr:id><gtr:impact>ENCALS is a network of ALS centres in Europe. It was established to help develop the standards of clinical and biomedical MND research across Europe and create a more collaborative environment for researchers, industry, funding agencies and Patient Associations. However, the meeting had a very transatlantic flavour, thanks to the participation of several of the leading researchers from North America.

With around 40 speakers, as well as numerous poster presentations, there is too much to cover in a few hundred words, so I'll focus on just a few of the key themes that were covered.</gtr:impact><gtr:outcomeId>56d9ca295f6b19.37436235</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.encals.eu/past-meeting/encals-meeting-2014-leuven/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>9237</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Healthcare</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>2DE2711E-6835-41E5-A0FB-546CFE511D89</gtr:id><gtr:outcomeId>5460f5bc6c17b7.67913009</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>78400</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>JPND ALS-CarE</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>JPND Research</gtr:fundingOrg><gtr:id>8A9BE418-E0FA-4116-BC3B-BE293AAE34D9</gtr:id><gtr:outcomeId>5460f5481f9274.45823641</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>277101</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA Project Grant (The UK National MND Registry)</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>5DC9A9D0-6E78-4495-AA57-7565C54E5CFF</gtr:id><gtr:outcomeId>5460f413573557.15319375</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>We developed an ALS staging system which is being refined within the ALS-CarE programme and applied within the STRENGTH programme. ALS Staging systems have been used for harmonised clinical trials training across Europe, for analysis of the timing of cognitive change in ALS, and for consultancy and advisory work for multiple pharmaceutical companies.</gtr:description><gtr:firstYearOfImpact>2015</gtr:firstYearOfImpact><gtr:id>690ACD8F-F679-4DAC-A57B-4BC58616FB1D</gtr:id><gtr:impactTypes><gtr:impactType>Economic,Policy &amp; public services</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56dee3f02266c7.96159674</gtr:outcomeId><gtr:sector>Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Staging for clinical practice and clinical trials</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C7871A51-CE94-4B48-89FD-A2C06D44F7B6</gtr:id><gtr:impact>The influence is a clinical staging system for ALS. This has been used by 12 European countries, all trained in assessment and certified. It has also been used for research and clinical practice in at least one US ALS clinic.</gtr:impact><gtr:outcomeId>56ded4dd2f5a71.01234103</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Standardised method for application of ALSFRS-R</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2D98783C-B70B-4120-AEDE-B1F638C34EF5</gtr:id><gtr:impact>The ALSFRS-R is a rating scale for assessing function in ALS. The influence is a standardised method for application of the ALSFRS-R, trained and certified across 12 European countries, ensuring standardised assessment and harmonised outcomes.</gtr:impact><gtr:outcomeId>56ded67940c4f5.36370128</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A latent class cluster analyses is a latent variable model where the latent variable is a categorical variable with k possible latent classes and the observed items are either categorical or continuous. It is used to classify ALS patients on the basis of the described variables into symptom clusters. In our study the cluster solution needs to be controlled for country. This is done by multi-group latent cluster modelling, which compares the structure of measurement models across groups (in this case: countries) and allows to control for differences between countries. It is similar to factorial invariance assessment in factor analyses.

Multi-group latent class cluster analyses were performed by including &amp;quot;country&amp;quot; as a categorical predictor variable of the latent class in the model (Kuha 2013).</gtr:description><gtr:id>476771DA-55F0-43AB-A2EE-E22328AE07B8</gtr:id><gtr:impact>For each cluster solution the measurement model equivalence with latent cluster probabilities varying between countries (proportion of clusters can differ between countries) but the same measurement model between countries (the relationship between items and latent variables is the same between countries) fits data best. After selecting the specification of the multi-group latent variable model the number of classes was determined by comparing goodness of fit measures. Figure 2 shows the information criteria (smaller is better model) for the different number of clusters. It can be seen that information criteria decrease with increasing number of clusters but decrease slows down after 4 to 5 clusters. After 5 clusters, clusters split in smaller ones or new clusters become extremely small. We therefore decided to select the 5 cluster solution which is similar to the previous studies. The entropy of the selected model was very good (0.95).</gtr:impact><gtr:outcomeId>56d9b8ce41a776.91713170</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Latent Class Cluster Analyses (LCCA)</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>A national population register capturing every case of ALS in the UK with clinical information</gtr:description><gtr:id>C0B5691F-EEA6-4F51-B574-CDD2C3C61940</gtr:id><gtr:impact>The database will be used as the basis of a funded research programme, AMBROSIA, designed to identify biomarkers for ALS</gtr:impact><gtr:outcomeId>56dedd92b66727.24138829</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>National MND Register</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Patients are stratified into clinical subgroups based on latent class cluster analysis of variables ascertained at first clinic visit. This strongly predicts survival, may predict genetic subgroups and can be replicated in multiple populations</gtr:description><gtr:id>F90D487B-0342-4872-B03E-BA6606D0B692</gtr:id><gtr:impact>This method is now used across European ALS research groups to stratify patients for research, and is being studied in two different programme grants as a stratification method.</gtr:impact><gtr:outcomeId>56dedc59855161.34993087</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Latent class cluster analysis</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>King's Clinical Staging is a system for describing ALS disease stage using simple clinical parameters. It was first published in 2012, but as a result of the award ALS-CarE, has been developed further, validated, used by multiple other research groups, and implemented into clinical practice internationally. It has also been used and developed for analysis of genetic outcomes in the award STRENGTH.</gtr:description><gtr:id>3DBF8E25-2FA7-4923-A8AD-E4964520B998</gtr:id><gtr:impact>1. Multiple other research groups have used this method for analysis (eg Association between estimated total daily energy expenditure and stage of amyotrophic lateral sclerosis.
Lee J et al. Nutrition. 2017 Jan;33:181-186. PMID: 27544003; Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study.
Ferraro D et al. Eur J Neurol. 2016 Sep;23(9):1426-32. PMID: 27238551; Neuropsychological assessment in different King's clinical stages of amyotrophic lateral sclerosis. Trojsi F et al. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3-4):228-35. PMID: 26905940 and others).

2. Several pharmaceutical companies have started to use the method as an outcome measure in clinical trials for ALS 

3. An academic led clinical trial is using ALS staging as an outcome measure

4. ALS Staging is now included as a formal outcome measure in international consensus guidelines from the World Federation of Neurology (see section 3 in URL below)</gtr:impact><gtr:outcomeId>58a2f17a6f1ad3.08113112</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>King's Clinical Staging for ALS</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:url>https://www.rarediseasesnetwork.org/cms/Portals/5/Final%20Draft%20of%20ALS%20CT%20Guidelines%20for%20Public%20Comments%207-19_1.pdf</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have applied a model derived from the cancer field to neurodegeneration. We have shown that ALS is a 6-step process rather than a dose-dependent process.</gtr:description><gtr:id>8C9FC393-AA66-4B24-844F-9B9BCFE858BB</gtr:id><gtr:impact>This represents a large change in the prevailing disease model and will allow new approaches for identification of risk factors and prevention strategies.</gtr:impact><gtr:outcomeId>5460fd41bd4795.47433952</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Multistage model of ALS</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:url>http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(14)70219-4/fulltext</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>We have developed a tool to convert clinical information into a unique global ID using SHA2 encryption. The method allows sharing of IDs between research groups to identify duplicates or match participants, without breaking anonymisation. It uses a salt to protect against brute force breaking of anonymity.</gtr:description><gtr:id>E332C7EE-AC05-4CB2-BDAC-67ED21410016</gtr:id><gtr:impact>This method is now being used across Europe in several studies including ALS-CarE, STRENGTH, the UK National MND Register and others, including retrospective application of the system to previous studies such as LiCALS and the UK MND DNA Bank, allowing further analyses to take place.</gtr:impact><gtr:outcomeId>58a2f2deaa9962.58422636</gtr:outcomeId><gtr:title>Unique global ID for ALS research</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A0B59FCA-8C39-4BD6-A801-960A5053D6F0</gtr:id><gtr:title>Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS).</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a1c3a4f7104f5aeaea8e8458de38e30"><gtr:id>7a1c3a4f7104f5aeaea8e8458de38e30</gtr:id><gtr:otherNames>Crockford C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>5a952c501667c1.34160462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D810042-210B-41AC-9DF6-1C873F7E7936</gtr:id><gtr:title>Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cce7e9524c9a17044255366d4761c6bb"><gtr:id>cce7e9524c9a17044255366d4761c6bb</gtr:id><gtr:otherNames>Kettemann D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>5aa8071f561729.22581075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84968D1F-7344-4446-A9C2-E003E4BC8A28</gtr:id><gtr:title>Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6e554bc59d628ea7e59537f8090ec1c"><gtr:id>a6e554bc59d628ea7e59537f8090ec1c</gtr:id><gtr:otherNames>Gaastra B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58a2d69a1cd4d5.90060636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>079E1AD5-B602-4D11-B768-4A4C8F08189C</gtr:id><gtr:title>Impact of disease, cognitive and behavioural factors on caregiver outcome in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/377a3ab4c08e576c4e06797dd1744485"><gtr:id>377a3ab4c08e576c4e06797dd1744485</gtr:id><gtr:otherNames>Watermeyer TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d71075a154f0.26780527</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7C5D845-8411-43DC-9742-33ADA82A29F2</gtr:id><gtr:title>Amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a885c902c57eeb35d266c592227182d7"><gtr:id>a885c902c57eeb35d266c592227182d7</gtr:id><gtr:otherNames>van Es MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5a952c5044d435.82097316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D030D75-F387-4251-AEA9-B8D25BE96CA2</gtr:id><gtr:title>Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5a952c50a55d64.44676013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99514A71-73D5-4D69-9605-E1C89BB260D0</gtr:id><gtr:title>Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba2675f7257ca9d3f840f3c2abd04605"><gtr:id>ba2675f7257ca9d3f840f3c2abd04605</gtr:id><gtr:otherNames>Rutter-Locher Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58a2db1a44e143.69165798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA7255F3-17BA-4EB4-9CD1-01900F6BB0C5</gtr:id><gtr:title>The El Escorial criteria: strengths and weaknesses.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcd7f0a51dffbc6cf4bb8006ed59d5f4"><gtr:id>dcd7f0a51dffbc6cf4bb8006ed59d5f4</gtr:id><gtr:otherNames>Agosta F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d7141621d533.60057897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>480EF240-8010-4F4A-900D-70EF70D146D6</gtr:id><gtr:title>A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa2841aab396cd2b4f18a94e7a29ae23"><gtr:id>aa2841aab396cd2b4f18a94e7a29ae23</gtr:id><gtr:otherNames>Morgan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5a952c5073e833.70304743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF433C31-7487-40D9-928C-FC5ACC49A89B</gtr:id><gtr:title>The evaluation of pain in amyotrophic lateral sclerosis: a case controlled observational study.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2bfcf87c109841d4d8f80742db55e3"><gtr:id>3a2bfcf87c109841d4d8f80742db55e3</gtr:id><gtr:otherNames>Wallace VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>545f8866de3cc7.85319985</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>708D1E0B-BE0E-493A-8892-7A0A66F061A8</gtr:id><gtr:title>Genetic testing in ALS: A survey of current practices.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea0d30c0d5552450e43cafc4c5b6e0de"><gtr:id>ea0d30c0d5552450e43cafc4c5b6e0de</gtr:id><gtr:otherNames>Vajda A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>58a2d251884a13.16559470</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0986240-D804-40FB-B8FE-0AD79D37E975</gtr:id><gtr:title>Commentary: Mapping the Human Exposome: Without It, How Can We Find Environmental Risk Factors for ALS?</gtr:title><gtr:parentPublicationTitle>Epidemiology (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7bc8538c82db76d6e2482ddeeb2d3d0"><gtr:id>d7bc8538c82db76d6e2482ddeeb2d3d0</gtr:id><gtr:otherNames>Al-Chalabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1044-3983</gtr:issn><gtr:outcomeId>56d70fdd6a34a3.77768821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BA47AC6-13DC-4667-9C84-1BA7079A7C06</gtr:id><gtr:title>Decision Making About Gastrostomy and Noninvasive Ventilation in Amyotrophic Lateral Sclerosis.</gtr:title><gtr:parentPublicationTitle>Qualitative health research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/287507cf26275f91e2ab1b48dbc45360"><gtr:id>287507cf26275f91e2ab1b48dbc45360</gtr:id><gtr:otherNames>Martin NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1049-7323</gtr:issn><gtr:outcomeId>56d7131f83a473.33694317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A6A6355-DB60-401D-8E04-CF692275B852</gtr:id><gtr:title>Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb87f110bb4914af0973f4d8272af1b6"><gtr:id>bb87f110bb4914af0973f4d8272af1b6</gtr:id><gtr:otherNames>Balendra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>545f87fdab4e07.34116956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64A0B6F7-18BA-488B-94B4-4AFA4A39CE10</gtr:id><gtr:title>Caregiver burden in amyotrophic lateral sclerosis: a cross-sectional investigation of predictors.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/248cd7b5834e2320f4863084d414aff4"><gtr:id>248cd7b5834e2320f4863084d414aff4</gtr:id><gtr:otherNames>Burke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5aa8072069bba0.28235050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DB0BAD0-3B08-457F-87B9-EC44A6202ED8</gtr:id><gtr:title>ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/150dbccb50bd7612b5f0fc6bffbc5ac6"><gtr:id>150dbccb50bd7612b5f0fc6bffbc5ac6</gtr:id><gtr:otherNames>Chi? A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5aa8072043d269.74818413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBC0796D-0423-46AD-AB21-656150451F40</gtr:id><gtr:title>Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>545f88674b8892.08246452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F061A5B-1E50-481F-BDEC-0DC091C7DF18</gtr:id><gtr:title>Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a7bfa806ecaa3aa93efd2103aa2e758"><gtr:id>0a7bfa806ecaa3aa93efd2103aa2e758</gtr:id><gtr:otherNames>Cirulli ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>56d71391f26f28.56685006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F943515-3A24-49FF-8437-058C23030B9B</gtr:id><gtr:title>The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fffef51a900e25e1e2fb7331e1518ade"><gtr:id>fffef51a900e25e1e2fb7331e1518ade</gtr:id><gtr:otherNames>Tramacere I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5aa807201c15f0.63723566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16EEBEA7-9695-4582-AB96-31DCCC8D8764</gtr:id><gtr:title>Accepting or declining non-invasive ventilation or gastrostomy in amyotrophic lateral sclerosis: patients' perspectives.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fadd0c8097e1eca6e33e0e3d9eb9bb00"><gtr:id>fadd0c8097e1eca6e33e0e3d9eb9bb00</gtr:id><gtr:otherNames>Greenaway LP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56d713b8bb1438.11217192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5111BA6-E93B-4595-9335-CF572303826F</gtr:id><gtr:title>Psychological as well as illness factors influence acceptance of non-invasive ventilation (NIV) and gastrostomy in amyotrophic lateral sclerosis (ALS): a prospective population study.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/287507cf26275f91e2ab1b48dbc45360"><gtr:id>287507cf26275f91e2ab1b48dbc45360</gtr:id><gtr:otherNames>Martin NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>545f87fd0df5a6.69048622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6756B2E-351B-488A-BF7C-EF48F605CF17</gtr:id><gtr:title>A clinical tool for predicting survival in ALS.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b659bff84a118cdf1b2c5f3638b599b"><gtr:id>3b659bff84a118cdf1b2c5f3638b599b</gtr:id><gtr:otherNames>Knibb JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>58a2d8cd9c5715.82850227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61590ECF-F8E2-446D-84F6-A4E50E77F91D</gtr:id><gtr:title>Physical activity and amyotrophic lateral sclerosis: a European population-based case-control study.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/971dc1cc54a770fc5f496d263f7728b7"><gtr:id>971dc1cc54a770fc5f496d263f7728b7</gtr:id><gtr:otherNames>Pupillo E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>545f87fd8661d8.21705823</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34CF535F-33A8-4DA8-AF96-E9ED0588BA14</gtr:id><gtr:title>Pain in amyotrophic lateral sclerosis</gtr:title><gtr:parentPublicationTitle>The Lancet Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/150dbccb50bd7612b5f0fc6bffbc5ac6"><gtr:id>150dbccb50bd7612b5f0fc6bffbc5ac6</gtr:id><gtr:otherNames>Chi? A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa8071f9032b4.38468532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EB1A1E4-A7E4-41E5-B0E8-5A8D518AC013</gtr:id><gtr:title>Elongator subunit 3 (ELP3) modifies ALS through tRNA modification.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3f91f5337bdb75081843c0f4fce157d"><gtr:id>e3f91f5337bdb75081843c0f4fce157d</gtr:id><gtr:otherNames>Bento-Abreu A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5a952c4f87d335.75359007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5335497A-BB64-4FBD-9575-73B3C8BFF18F</gtr:id><gtr:title>Intermediate length C9orf72 expansion in an ALS patient without classical C9orf72 neuropathology.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8be76b4be2b2f7cd39c6b62a634ab40b"><gtr:id>8be76b4be2b2f7cd39c6b62a634ab40b</gtr:id><gtr:otherNames>Beer AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d7143b166b69.28978885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA587352-D2C1-4328-97E3-31D8BA28FC55</gtr:id><gtr:title>A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0820ba371c3d623629717b3bc9288d69"><gtr:id>0820ba371c3d623629717b3bc9288d69</gtr:id><gtr:otherNames>McGeachan AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58a2d6e1199e56.30629501</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>122534B3-E6FA-46F1-ADC2-3D8C97DF420B</gtr:id><gtr:title>Executive dysfunction predicts social cognition impairment in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/377a3ab4c08e576c4e06797dd1744485"><gtr:id>377a3ab4c08e576c4e06797dd1744485</gtr:id><gtr:otherNames>Watermeyer TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56d712cf434233.91292776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5249FEB-9FE5-47F3-8AD9-B391C17E5B8D</gtr:id><gtr:title>Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb87f110bb4914af0973f4d8272af1b6"><gtr:id>bb87f110bb4914af0973f4d8272af1b6</gtr:id><gtr:otherNames>Balendra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>545f87fcb61572.96405314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBE80EBF-69E2-4E7D-832F-1423374FDA23</gtr:id><gtr:title>Patient journey to a specialist amyotrophic lateral sclerosis multidisciplinary clinic: an exploratory study.</gtr:title><gtr:parentPublicationTitle>BMC health services research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2025164d8f6b6a34f4d969292d3b99b2"><gtr:id>2025164d8f6b6a34f4d969292d3b99b2</gtr:id><gtr:otherNames>Galvin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1472-6963</gtr:issn><gtr:outcomeId>5aa80720d29124.01044496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>245AE233-C237-41A3-BC80-671176B2436F</gtr:id><gtr:title>Investigation of next-generation sequencing technologies as a diagnostic tool for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa2841aab396cd2b4f18a94e7a29ae23"><gtr:id>aa2841aab396cd2b4f18a94e7a29ae23</gtr:id><gtr:otherNames>Morgan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d713d90d5f93.26997419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3480669-3F34-459D-B5AD-0FDC4DD50432</gtr:id><gtr:title>Gene discovery in amyotrophic lateral sclerosis: implications for clinical management.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7bc8538c82db76d6e2482ddeeb2d3d0"><gtr:id>d7bc8538c82db76d6e2482ddeeb2d3d0</gtr:id><gtr:otherNames>Al-Chalabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>58a2d505b97122.41464612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4A9D427-6132-4832-96EA-08057BA6CDF1</gtr:id><gtr:title>Comparison of the King's and MiToS staging systems for ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65b06f62a28aa16278494b24ff99202a"><gtr:id>65b06f62a28aa16278494b24ff99202a</gtr:id><gtr:otherNames>Fang T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58a2d34f61ed56.81408828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB8EF252-9B87-41CE-BC10-FAFB760AACAB</gtr:id><gtr:title>Genetic correlation between amyotrophic lateral sclerosis and schizophrenia.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/150e9e10e3ebe78c54e55b675bce02c7"><gtr:id>150e9e10e3ebe78c54e55b675bce02c7</gtr:id><gtr:otherNames>McLaughlin RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a952c50e53794.65775672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC605C9E-6CE8-4228-85DD-232BE40ED854</gtr:id><gtr:title>Targeted Genetic Screen in Amyotrophic Lateral Sclerosis Reveals Novel Genetic Variants with Synergistic Effect on Clinical Phenotype.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn><gtr:outcomeId>5a952c51458230.49094954</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39546F9C-81F7-445F-94A7-5F07221163D1</gtr:id><gtr:title>The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3617d8d8a839d289a3d354c415cb2d67"><gtr:id>3617d8d8a839d289a3d354c415cb2d67</gtr:id><gtr:otherNames>Lill CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>56d712ed6da9f1.05074125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F80FC6C-D36C-40BD-957F-DE7CAA3EF54D</gtr:id><gtr:title>The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d03ffb9b885afe6a58631746bc84369"><gtr:id>1d03ffb9b885afe6a58631746bc84369</gtr:id><gtr:otherNames>Proudfoot M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58a2dcc5e3e0f2.77504760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>133F60E0-0319-4991-B23F-3725588B9A6D</gtr:id><gtr:title>Amyotrophic lateral sclerosis: A higher than expected incidence in people over 80 years of age.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa1291a1562a98cfeae8059f6c6f24d2"><gtr:id>fa1291a1562a98cfeae8059f6c6f24d2</gtr:id><gtr:otherNames>Aragones JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58a2dad7a8ad25.92099177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA7ACFAC-2E7A-48AF-AE5E-90B0DA35B1DA</gtr:id><gtr:title>ECAS A-B-C: alternate forms of the Edinburgh Cognitive and Behavioural ALS Screen.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/455ef8efa672886fda5e194a1e51f698"><gtr:id>455ef8efa672886fda5e194a1e51f698</gtr:id><gtr:otherNames>Crockford CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>5a952c4fd11e84.04323575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>526F0459-43E0-40B8-83F0-FFF1B88E30D0</gtr:id><gtr:title>C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bc40f7ec51e8c45e1a0d464e57ce8e5"><gtr:id>4bc40f7ec51e8c45e1a0d464e57ce8e5</gtr:id><gtr:otherNames>Rooney J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>58a2d5bd6dca00.65121282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8CE34B7-6E78-42BA-BE41-930460D5150E</gtr:id><gtr:title>Endogenous retroviruses in ALS: A reawakening?</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d729a484cb0fe4fe383cf87903ed1c6"><gtr:id>0d729a484cb0fe4fe383cf87903ed1c6</gtr:id><gtr:otherNames>Brown RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>56d70f5bc12d35.22474705</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>126907ED-9F16-457E-91A6-AA6920293088</gtr:id><gtr:title>A novel Alzheimer disease locus located near the gene encoding tau protein.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e3a671aa40c3ab6ceb98c09b75b6095"><gtr:id>3e3a671aa40c3ab6ceb98c09b75b6095</gtr:id><gtr:otherNames>Jun G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>56d71365bc0707.31531951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9D5FDE9-122A-42CF-A227-8A08479D6014</gtr:id><gtr:title>A mapping review of international guidance on the management and care of amyotrophic lateral sclerosis (ALS).</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c684346a8ade1d09b97cc2ea3bf143c5"><gtr:id>c684346a8ade1d09b97cc2ea3bf143c5</gtr:id><gtr:otherNames>Janssens AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58a2dc453ae997.01214161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33318660-20D7-47FB-BEC9-D983A7D75788</gtr:id><gtr:title>Establishing the UK DNA Bank for motor neuron disease (MND).</gtr:title><gtr:parentPublicationTitle>BMC genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d800fe2353c2fd435d4e9f68af2a0c5d"><gtr:id>d800fe2353c2fd435d4e9f68af2a0c5d</gtr:id><gtr:otherNames>Smith L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2156</gtr:issn><gtr:outcomeId>56d71159a571c4.56016852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94D412F5-FA06-4B65-AEC1-4CDEEF035A09</gtr:id><gtr:title>Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/922738046572c98b4498b0faf60a5115"><gtr:id>922738046572c98b4498b0faf60a5115</gtr:id><gtr:otherNames>van der Kleij LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d711d6233b42.00938309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2218FCB-0223-4130-A1A3-78535D4B1909</gtr:id><gtr:title>Novel mutations support a role for Profilin 1 in the pathogenesis of ALS.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d713f6a86069.54355929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92721F9D-F86B-4A00-BE5B-9E00F0CC7C4E</gtr:id><gtr:title>The changing picture of amyotrophic lateral sclerosis: lessons from European registers.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7cf07ee1b4f01b1801bba4f285fded5"><gtr:id>d7cf07ee1b4f01b1801bba4f285fded5</gtr:id><gtr:otherNames>Hardiman O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5a952cbf3d3489.76839888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FB4C919-21C6-413A-BB3B-50038BEDB6D1</gtr:id><gtr:title>Amyotrophic lateral sclerosis: moving towards a new classification system.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7bc8538c82db76d6e2482ddeeb2d3d0"><gtr:id>d7bc8538c82db76d6e2482ddeeb2d3d0</gtr:id><gtr:otherNames>Al-Chalabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>58a2d6364285b7.56024280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97344F88-648D-4C77-AD68-60C1A873CF3B</gtr:id><gtr:title>Quantitative interaction proteomics of neurodegenerative disease proteins.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0f118fe1d7289a14a5998bdd80aaca2"><gtr:id>d0f118fe1d7289a14a5998bdd80aaca2</gtr:id><gtr:otherNames>Hosp F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d712907e4558.44490630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B597D463-D882-445E-BBAB-FE566B93D355</gtr:id><gtr:title>How integrated are neurology and palliative care services? Results of a multicentre mapping exercise.</gtr:title><gtr:parentPublicationTitle>BMC neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b44accbf6b8f7fc00dc9201bd1931987"><gtr:id>b44accbf6b8f7fc00dc9201bd1931987</gtr:id><gtr:otherNames>van Vliet LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2377</gtr:issn><gtr:outcomeId>58a2db6cb6a046.94436382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74DB89D8-3962-4943-B83A-C015730EF54A</gtr:id><gtr:title>Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5a699108cccc63f5bf4495f272d4bd3"><gtr:id>c5a699108cccc63f5bf4495f272d4bd3</gtr:id><gtr:otherNames>Prins BP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>58a2d9efae6d14.43409813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68ADC5D8-3052-4B10-8666-C78674C65378</gtr:id><gtr:title>Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3251657938f8056db79b6c1e54c6ed66"><gtr:id>3251657938f8056db79b6c1e54c6ed66</gtr:id><gtr:otherNames>ProGas Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>56d7123ef3c612.56203782</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FB28EEC-DD93-4531-B625-2E6A6F7974E6</gtr:id><gtr:title>Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7bc8538c82db76d6e2482ddeeb2d3d0"><gtr:id>d7bc8538c82db76d6e2482ddeeb2d3d0</gtr:id><gtr:otherNames>Al-Chalabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>545f886725c9e6.48809756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>029131C3-5262-4725-B8A5-E6DD7D7C9CFA</gtr:id><gtr:title>Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0f71bff1be428cd8369af4da4057398"><gtr:id>b0f71bff1be428cd8369af4da4057398</gtr:id><gtr:otherNames>?stergaard SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>56d71206274fb8.33768976</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECFADA25-61D1-4E1C-A8EF-72FC2650A8BB</gtr:id><gtr:title>Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189b1ab3fec05c8e5670388f3356335d"><gtr:id>189b1ab3fec05c8e5670388f3356335d</gtr:id><gtr:otherNames>Jones AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>545f87fd5d16b2.20381782</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09280C5F-1C2F-4629-BD6F-8A75501423D1</gtr:id><gtr:title>Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients.</gtr:title><gtr:parentPublicationTitle>Neuromolecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f4312da8d92a745d0fcdbc40991e28f"><gtr:id>8f4312da8d92a745d0fcdbc40991e28f</gtr:id><gtr:otherNames>Benigni M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1535-1084</gtr:issn><gtr:outcomeId>58a2dbcae11b89.32807465</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A20EFD13-7243-448C-8387-588CBC102D82</gtr:id><gtr:title>Evidence of an environmental effect on survival in ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c398b2323889da25d02c67f44bc8075"><gtr:id>4c398b2323889da25d02c67f44bc8075</gtr:id><gtr:otherNames>Keren N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>545f88668aead8.28750753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3DF8548-04A2-4856-A4A3-F848103A5053</gtr:id><gtr:title>The CHCHD10 P34S variant is not associated with ALS in a UK cohort of familial and sporadic patients.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a1becffcc1571868d22b707ce216d4c"><gtr:id>5a1becffcc1571868d22b707ce216d4c</gtr:id><gtr:otherNames>Wong CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d7102d11d112.08347350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DB49E4E-6DA9-4874-BE0D-0262912A723A</gtr:id><gtr:title>Proposed association between the hexanucleotide repeat of C9orf72 and opposability index of the thumb.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbfbba64e0bed5a5bd0e165199be7334"><gtr:id>bbfbba64e0bed5a5bd0e165199be7334</gtr:id><gtr:otherNames>Chen Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58a2d484e24286.26421323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1570BEA-A10B-492A-A9B1-8943449C6E69</gtr:id><gtr:title>Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6883810a16e61c37ff340736f6cdf792"><gtr:id>6883810a16e61c37ff340736f6cdf792</gtr:id><gtr:otherNames>van Rheenen W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>58a2d7f849c822.53353278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C227975-38FC-4661-A027-C0B4241CCF73</gtr:id><gtr:title>Stratified gene expression analysis identifies major amyotrophic lateral sclerosis genes.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189b1ab3fec05c8e5670388f3356335d"><gtr:id>189b1ab3fec05c8e5670388f3356335d</gtr:id><gtr:otherNames>Jones AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d71342a3b433.63311783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23EB52D3-42D5-4D95-92F5-7E3345F86A99</gtr:id><gtr:title>Psychotherapy and pharmacotherapy interventions to reduce distress or improve well-being in people with amyotrophic lateral sclerosis: A systematic review.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad90181f9362eec2732ea7ce48124372"><gtr:id>ad90181f9362eec2732ea7ce48124372</gtr:id><gtr:otherNames>Gould RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d710cb8d5832.47820823</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">ES/L008238/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>7D5D2DB2-0A64-42AF-A644-5F541B832A29</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Economics</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>5858EC49-4786-4440-8352-1AB0B6DC5F23</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Psychology</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>EFFEC6B1-6BC8-4C9D-9D77-02CEF5E4E301</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomedical neuroscience</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>0A51EF84-2B22-45D2-B583-F65878427D68</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Gerontology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>DA22549B-026D-41FC-9204-F0CC6913B24D</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Health Psychology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>E398036B-8D9A-43E0-BBBA-AF0932365C69</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Public economics</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>